📈 Markets Bloom, Tariffs Loom
As we near the end of March, the markets are moving as fast as the seasons are changing.
Markets Bloom, Tariffs Loom: This Week’s Investor Rundown
As we near the end of March, the markets are moving as fast as the seasons are changing. Gold is flirting with new record highs, pharma stocks are proving resilient, and U.S. trade policy is once again in the spotlight thanks to a fresh round of tariffs. From resource-rich rallies to sector shakeups, this week’s market pulse is packed with opportunity and a healthy dose of uncertainty.
Whether you’re tightening up your strategy or scouting the next breakout play, we’ve got the latest insights in Mining, Tech, ETFs, Bio, and more to keep you a step ahead.
Stay sharp with B-TV’s latest feature.
Visit www.b-tv.com for exclusive updates and breaking news, helping you make informed investment decisions before the rest of the market catches on.
Let’s see where the markets take us next.
3 Minute Read:
Here's how some major markets/indexes performed in the last 5-days:
- Dow Jones: 41,544 (-1.51)
- Nasdaq 100: 19,269 (-3.86%)
- TSX: 24,783 (-1.10%)
- BTC: 83,747 (-2.65%)
- Ethereum: 1,875 (-6.43%)
(USD)
As of 03/28/2025 at 10:30AM PST
Auto Tariffs Put Markets Back in Drive
Tariff talk has revved back up. President Trump announced a 25% tariff on imported vehicles starting April 3, and on auto parts by May 3, an unexpected move that sent markets wobbling midweek.
Why it matters: Imported cars make up nearly half of all U.S. vehicle sales, and foreign made parts are used in over 60% of U.S. assembled vehicles. These new levies could drive up costs across the board, impacting automakers, suppliers, and consumers alike.
-Mar-27-2025-11-12-31-6593-PM.avif)
The Canadian angle: Canada exports more cars to the U.S. than any other country, meaning the new tariffs could hit Ontario’s auto industry particularly hard. So far, there’s no official exemption.
Big picture: Tariff surprises are once again shaking up investor sentiment. While broader indexes remain up week-over-week, growing policy uncertainty may keep markets on edge heading into Q2.
Pharma keeps its pulse
The biotech and pharmaceutical sector continues to show resilience even as geopolitical headwinds stir. While merger activity has slowed due to uncertainty around tariffs and leadership in Washington, analysts say the long-term outlook remains bright.
One major catalyst? The continued rise of GLP-1 weight-loss drugs like Zepbound and Wegovy. A new study shows these treatments can deliver even better results when paired with coaching, which could open the door to broader adoption and improved outcomes.
Why it matters:
Investors may be cautious amid short-term policy volatility, but the fundamentals are still there. Pharma companies are accelerating shipments, product innovation is strong, and global demand hasn’t skipped a beat. That’s keeping the sector on track for growth—even as other areas of the market tread water.
Lexaria Bioscience is setting new standards in drug delivery with its patented DehydraTECH™ oral technology, optimizing absorption for GLP-1 and other high-demand drugs.
Gold’s Moment in the Spotlight
Gold is having a main character moment. Prices have surged past US$2,400 an ounce, setting yet another record as investors look for safety amid global trade tensions and macro uncertainty. And according to Wall Street’s top players, the rally may be just getting started.
Goldman Sachs raised its year-end forecast to as high as US$3,500, while Bank of America echoed similar optimism, citing a jump in investment demand. Some are even floating the idea that gold could top US$4,500 in extreme scenarios, driven by constrained supply and surging global interest.
Why it matters: Gold isn’t just tracking the U.S. dollar or rate expectations anymore. Analysts are starting to price it based on real demand fundamentals. With major economies eyeing resource independence and mining M&A heating up, this could mark the start of a longer-term gold supercycle.
For investors, it’s a reminder that sometimes, the oldest assets can offer the newest opportunities.
.avif)
Copper Fox Metals is focused on advancing large-scale copper projects in North America, with a strategy to take assets to the PFS stage before securing development partners.
Valkea Resources is focused on gold exploration in Central Lapland and Northern Finland, identifying new zones with promising drill results as the region gains global attention for its resource potential.
📢 This Week's Selected Company News:
Yukon Metals Upsizes Private Placement to C$10M
Yukon Metals has increased its previously announced non-brokered private placement from C$5 million to up to C$10 million due to strong investor interest. Proceeds will support ongoing exploration and development across its Yukon portfolio.
B2Gold Updates Goose Project Plans
B2Gold has released an updated mineral reserve and life-of-mine plan for its Goose Project in Nunavut. The company is also launching a study to explore expanding mill throughput and reaffirmed its construction and development cost estimate of C$540 million. First gold pour remains on track for Q1 2026.
Medicus Pharma Secures $4.2M in Reg A Offering
Medicus Pharma has closed its $4.2 million Regulation A offering, providing fresh capital to advance its clinical pipeline. The company continues to build momentum in its mission to tackle major global health challenges through innovative therapeutics.
📬 That’s a wrap for this week!
Want more? Visit www.b-tv.com and subscribe for breaking updates, company features, and actionable insights straight from the market’s front lines.
What sector are you interested in? BTV wants to know! Send your thoughts here!
Looking forward to hearing from you!
Until next time!
